ipharmacenter Consulting services

Eli Lilly has entered a definitive agreement to acquire Ventyx Biosciences in an all‑cash transaction valued at approximately 1.2 billion dollars, aiming to strengthen its position in orally delivered therapies for chronic, inflammation‑mediated diseases. Ventyx contributes a differentiated portfolio of small‑molecule oral candidates targeting autoimmune, inflammatory and neurodegenerative diseases, centered on NLRP3 inhibition and advanced IBD assets. iPharmaCenter Consultin

GSK announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for adults and adolescents aged 12 years and older with severe asthma characterized by an eosinophilic phenotype. Exdensur stands out as the first ultra-long-acting biologic therapy for severe asthma, designed for twice-yearly dosing, offering patients a more convenient treatment schedule compared with currently available biologics. Clinical

GSK has announced encouraging results from its phase III clinical trials, ANCHOR-1 and ANCHOR-2, for depemokimab in treating chronic...

January 08, 2024 AbbVie aims to bring another HS therapy after Humira, announced positive Phase 2 trial of lutikizumab Positive outcomes...

AbbVie aims to advance its immunology pipeline by initiating a global Phase 3 trial of Rinvoq (upadacitinib) for Hidradenitis Suppurativa...

Eli Lilly announced the positive results of Phase 3 clinical trial of its drug, lebrikizumab, in treating atopic dermatitis. There was a...

AbbVie announced it would move Rinvoq (upadacitinib) into Phase 3 clinical trials to treat systemic lupus erythematosus (SLE). Rinvoq is...

EMA takes measures to reduce the risk of severe side effects with JAK inhibitors. The Committee for Medicinal Products for Human Use...

AbbVie published Phase 3 clinical trials of Skyrizi in Crohn's Disease. AbbVie announced that The Lancet had published the induction and...

AbbVie's immunology portfolio in Europe is strengthened with Skyrizi approval for psoriatic arthritis Approval is based on the trial...